Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

NCT04868877 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

194

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer Metastatic
Gastric Cancer
Esophageal Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
Colorectal Cancer

Interventions

DRUG: MCLA-129
DRUG: Osimertinib
DRUG: Chemotherapy

Sponsor

Merus B.V.